Please login to the form below

Not currently logged in

Celgene pays $300m upfront for immunology start-up Delinia

Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

Celgene has made another bolt-on acquisition, paying $300m upfront and $475m in milestones for Delinia and its immunology and inflammation programmes.

The scale of the deal is eye-opening given that Delinia's lead candidate is still in preclinical development and the company itself  - led by Atlas Ventures' Saurabh Saha - only came into being a few months ago.

Celgene has made no secret of its intention to expand its pipeline beyond its main focus on cancer drugs, and the Delinia deal gives it a candidate, called DEL106, that acts as an interleukin-2 (IL-2) mutein Fc fusion protein and is designed to up-regulate regulatory T cell function.

The drug has potential in a variety of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, says Celgene, which also claims rights to related second-generation candidates. DEL106 is due to start clinical trials in 2018.

Celgene's first foray into the immunology and inflammation sector came with psoriasis blockbuster Otezla (apremilast), and it has a string of other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.

Otezla continued its fast growth trajectory with sales of $305m in the fourth quarter, up 67%, which helped the US biotech post a 17% increase in product sales to $2.98bn. Star oncology drug Revlimid (lenalidomide) for blood cancer grew 16% to $1.81bn in the quarter, with follow-up Pomalyst/Innovid (pomalidomide) up 29% to $378m.

The Delinia acquisition comes in the wake of other bolt-on deals most recently its takeover earlier this month of another immunology specialist - Anokion - and its December purchase of oncology, neurodegeneration and autoimmune disease firm Acetylon and a $295m discovery alliance with Evotec for stem cell therapies.

It's still adding to its cancer stable too, with recent examples including its $600m deal for Swiss biotech EngMab - signed last October - the acquisition of marizomib from Triphase Accelerator for $43.5m and a $2.5bn licensing deal with Jounce for five immuno-oncology candidates.

"2016 was an outstanding year of progress strengthening our commercial portfolio and advancing our early-, mid- and late-stage pipeline," said Mark Alles, Celgene's chief executive.

"We expect our business momentum and significant near-term catalysts to drive high-growth through 2017 and beyond."

Article by
Phil Taylor

27th January 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...